by The Menstrual Cramps Treatment Market is estimated to be valued at US$ 652.3 Mn in 2023 and is expected to exhibit a CAGR of 4.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Menstrual cramps treatment is meant for temporary relief from pain and discomfort associated with menstrual periods. It includes prescription and over-the-counter pain medications such as NSAIDs, oral contraceptives and contraceptive patches and implants, heating pads, and nutritional supplements. Drugs like NSAIDs are most commonly used for treatment as they inhibit prostaglandin activity thus reducing muscle contractions in the uterus.
Market key trends:
The menstrual cramps treatment market is witnessing high growth owing to the trend towards less invasive treatment options. There is increasing adoption of contraceptive implants and patches for menstrual cramps relief as they provide long-term benefits with fewer side effects compared to oral contraceptives. Contraceptive patches slowly release hormones through the skin while contraceptive implants inserted under the skin of upper arm can prevent pregnancy for 3 to 5 years. They have shown great effectiveness for relieving painful periods. Furthermore, preference for alternative therapies like acupuncture, massage, yoga and supplements is on the rise as patients seek natural solutions to menstrual cramps. Studies have proved efficacy of omega-3 fatty acids, ginger, magnesium and B complex supplements in reducing intensity of cramps.
Porter’s Analysis
Threat of new entrants: Low capital requirement and established buyer habits pose low threat of new entrants in the menstrual cramps treatment market.
Bargaining power of buyers: Buyers have moderate bargaining power due to availability of diverse product offerings by key market players at different price points.
Bargaining power of suppliers: Suppliers have low bargaining power due to presence of several raw material suppliers in the market.
Threat of new substitutes: Moderate threat from substitutes like pain relief medication and alternative pain relief and relaxation techniques.
Competitive rivalry: High due to presence of global and regional players offering varied product portfolios in menstrual cramps treatment market.
SWOT Analysis
Strength: Wide product portfolios and strong brand recognition of key players.
Weakness: Side effects associated with drug therapy and contraceptive medications.
Opportunity: Untapped growth potential in emerging economies and rising awareness about relaxation techniques.
Threats: Stringent regulatory framework governing contraceptive medications and introduction of alternative pain relief methods.
Key Takeaways
The Global Menstrual Cramps Treatment Market Growth is expected to witness high, exhibiting CAGR of 4.4% over the forecast period, due to increasing prevalence of dysmenorrhea among young girls and working women. The Asia Pacific region dominates the global market and is expected to continue its dominance over the forecast period, owing to rising disposable income, growing awareness about menstrual health management, and increasing adoption of contraceptives in countries like India and China.
Regionally, the Asia Pacific menstrual cramps treatment market is projected to witness the fastest growth, expanding at a CAGR of around 5.1% over the next eight years. Factors such as improving healthcare infrastructure, growing number of reproductive age population and rising disposable income, are driving the Asia Pacific menstrual cramps treatment market.
Key players operating in the menstrual cramps treatment market are Stryker Corporation, SATELEC (Actongroup), Surgiform Innovative Surgical Products, Allergan (Abbvie) Luminera, Implantech, Koken, ANTHONY PRODUCTS INC., NOUVAG, Sihuan Pharmaceutical Holdings Group Ltd., and Other prominent players. These players are focused on developing advanced treatment options and expanding geographically to strengthen their market position.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
